London WB - Search Results

1

MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.

Xue C, Yu DM, Gherardi S, Koach J, Milazzo G, Gamble L, Liu B, Valli E, Russell AJ, London WB, Liu T, Cheung BB, Marshall GM, Perini G, Haber M, Norris MD. Xue C, et al. Among authors: london wb. Oncotarget. 2016 Aug 23;7(34):54937-54951. doi: 10.18632/oncotarget.10709. Oncotarget. 2016. PMID: 27448979 Free PMC article.

2

MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN.

Cohn SL, London WB, Huang D, Katzenstein HM, Salwen HR, Reinhart T, Madafiglio J, Marshall GM, Norris MD, Haber M. Cohn SL, et al. Among authors: london wb. J Clin Oncol. 2000 Nov 1;18(21):3604-13. doi: 10.1200/JCO.2000.18.21.3604. J Clin Oncol. 2000. PMID: 11054433

3

Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro.

Norris MD, Smith J, Tanabe K, Tobin P, Flemming C, Scheffer GL, Wielinga P, Cohn SL, London WB, Marshall GM, Allen JD, Haber M. Norris MD, et al. Among authors: london wb. Mol Cancer Ther. 2005 Apr;4(4):547-53. doi: 10.1158/1535-7163.MCT-04-0161. Mol Cancer Ther. 2005. PMID: 15827327

4

Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.

George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L, Brodeur GM, Castleberry RP, Look AT. George RE, et al. Among authors: london wb. J Clin Oncol. 2005 Sep 20;23(27):6466-73. doi: 10.1200/JCO.2005.05.582. Epub 2005 Aug 22. J Clin Oncol. 2005. PMID: 16116152 Clinical Trial.

5

Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma.

Haber M, Smith J, Bordow SB, Flemming C, Cohn SL, London WB, Marshall GM, Norris MD. Haber M, et al. Among authors: london wb. J Clin Oncol. 2006 Apr 1;24(10):1546-53. doi: 10.1200/JCO.2005.01.6196. J Clin Oncol. 2006. PMID: 16575006

6

ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.

Hogarty MD, Norris MD, Davis K, Liu X, Evageliou NF, Hayes CS, Pawel B, Guo R, Zhao H, Sekyere E, Keating J, Thomas W, Cheng NC, Murray J, Smith J, Sutton R, Venn N, London WB, Buxton A, Gilmour SK, Marshall GM, Haber M. Hogarty MD, et al. Among authors: london wb. Cancer Res. 2008 Dec 1;68(23):9735-45. doi: 10.1158/0008-5472.CAN-07-6866. Cancer Res. 2008. PMID: 19047152 Free PMC article.

7

International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee.

Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, Schleiermacher G, Speleman F, Spitz R, London WB, Cohn SL, Pearson AD, Maris JM. Ambros PF, et al. Among authors: london wb. Br J Cancer. 2009 May 5;100(9):1471-82. doi: 10.1038/sj.bjc.6605014. Br J Cancer. 2009. PMID: 19401703 Free PMC article.

8

Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project.

London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, Berthold F, Nakagawara A, Ladenstein RL, Iehara T, Matthay KK. London WB, et al. J Clin Oncol. 2011 Aug 20;29(24):3286-92. doi: 10.1200/JCO.2010.34.3392. Epub 2011 Jul 18. J Clin Oncol. 2011. PMID: 21768459 Free PMC article.

9

ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux.

Henderson MJ, Haber M, Porro A, Munoz MA, Iraci N, Xue C, Murray J, Flemming CL, Smith J, Fletcher JI, Gherardi S, Kwek CK, Russell AJ, Valli E, London WB, Buxton AB, Ashton LJ, Sartorelli AC, Cohn SL, Schwab M, Marshall GM, Perini G, Norris MD. Henderson MJ, et al. Among authors: london wb. J Natl Cancer Inst. 2011 Aug 17;103(16):1236-51. doi: 10.1093/jnci/djr256. Epub 2011 Jul 28. J Natl Cancer Inst. 2011. PMID: 21799180 Free PMC article.

10

N-Myc regulates expression of the detoxifying enzyme glutathione transferase GSTP1, a marker of poor outcome in neuroblastoma.

Fletcher JI, Gherardi S, Murray J, Burkhart CA, Russell A, Valli E, Smith J, Oberthuer A, Ashton LJ, London WB, Marshall GM, Norris MD, Perini G, Haber M. Fletcher JI, et al. Among authors: london wb. Cancer Res. 2012 Feb 15;72(4):845-53. doi: 10.1158/0008-5472.CAN-11-1885. Epub 2011 Dec 27. Cancer Res. 2012. PMID: 22202125

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

256 results

Search Page

Filters